- Home
- LANV vs ANNX Comparison
LANV vs ANNX Comparison
Compare LANV & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- ANNX
- Stock Information
- Founded
- LANV 2015
- ANNX 2011
- Country
- LANV China
- ANNX United States
- Employees
- LANV N/A
- ANNX N/A
- Industry
- LANV Blank Checks
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- LANV Finance
- ANNX Health Care
- Exchange
- LANV Nasdaq
- ANNX Nasdaq
- Market Cap
- LANV 275.9M
- ANNX 263.3M
- IPO Year
- LANV N/A
- ANNX 2020
- Fundamental
- Price
- LANV $2.30
- ANNX $2.51
- Analyst Decision
- LANV
- ANNX Strong Buy
- Analyst Count
- LANV 0
- ANNX 4
- Target Price
- LANV N/A
- ANNX $12.50
- AVG Volume (30 Days)
- LANV 46.3K
- ANNX 1.9M
- Earning Date
- LANV 08-25-2025
- ANNX 08-11-2025
- Dividend Yield
- LANV N/A
- ANNX N/A
- EPS Growth
- LANV N/A
- ANNX N/A
- EPS
- LANV N/A
- ANNX N/A
- Revenue
- LANV $340,211,202.00
- ANNX N/A
- Revenue This Year
- LANV $11.74
- ANNX N/A
- Revenue Next Year
- LANV $11.11
- ANNX N/A
- P/E Ratio
- LANV N/A
- ANNX N/A
- Revenue Growth
- LANV N/A
- ANNX N/A
- 52 Week Low
- LANV $0.91
- ANNX $1.29
- 52 Week High
- LANV $2.69
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- LANV 48.12
- ANNX 51.40
- Support Level
- LANV $2.36
- ANNX $2.21
- Resistance Level
- LANV $2.51
- ANNX $2.68
- Average True Range (ATR)
- LANV 0.21
- ANNX 0.25
- MACD
- LANV -0.01
- ANNX -0.02
- Stochastic Oscillator
- LANV 45.76
- ANNX 59.19
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.